Grace Therapeutics, the Princeton, New Jersey-based biopharma company developing GTx-104 for aneurysmal subarachnoid hemorrhage, has announced a $10 million private placement, pricing 4,761,904 shares at $2.10 each with new and existing investors. The company says the money extends its cash runway through the end of 2028, funding the specific work needed to get GTx-104 back in front of the FDA after an earlier rejection that had nothing to do with whether the drug actually works.
The Deal
Craig-Hallum served as the sole placement agent on the raise, which is expected to close August 6, 2026, subject to customary closing conditions. Grace didn’t name the specific investors involved, describing them only as new and existing “fundamental investors.” Net proceeds are earmarked specifically for manufacturing and regulatory work tied to advancing GTx-104 toward resubmission , a fairly tight, purpose-built use of proceeds for a company at this stage
Why the Money Is Needed Right Now
This financing only makes sense in light of what happened earlier this year. In April 2026, GTx-104 received a Complete Response Letter from the FDA, but the issues cited weren’t about safety or efficacy. They were manufacturing-related: cGMP compliance deficiencies at the contract manufacturer, a need for additional leachables data time points, and further toxicology work on excipient risk. That’s a meaningfully different situation than a clinical setback, since it means the underlying drug and its trial data aren’t in question, the production process around it is.
Grace’s response has been to pursue a dual-source manufacturing strategy: remediating the issues at its existing contract manufacturer while simultaneously transferring the technology to a second, U.S.-based manufacturer, so the company isn’t dependent on a single facility for its path back to the FDA. CEO Prashant Kohli laid out that logic plainly when the company disclosed its FDA Type A meeting minutes: “We have a clear view of what is required and are executing against it, including advancing a second manufacturing source in the United States so that we are not dependent on a single path to resubmission.” He also added “We will report progress as key milestones are achieved. If approved, GTx-104 would represent a meaningful innovation in the care for aSAH, and we are committed to improving outcomes for aSAH patients”
What GTx-104 Actually Is
GTx-104 is a clinical-stage, injectable formulation of nimodipine designed for intravenous infusion, targeting aneurysmal subarachnoid hemorrhage, a serious and often sudden brain bleed with a narrow treatment window. More than 200 patients and volunteers have received the drug across its development to date, and it carries Orphan Drug Designation along with 52 granted or pending patents. Grace, which develops novel drug delivery technologies aimed at rare and orphan diseases more broadly, is a late-stage company on Nasdaq under the ticker GRCE, with GTx-104 as its lead and most advanced asset.
The Bigger Picture
A Complete Response Letter is never good news, but a manufacturing-focused CRL is about as recoverable a version of that setback as a company can get, since it doesn’t reopen questions about the drug’s clinical profile. This financing is Grace essentially buying itself the runway to run two manufacturing pathways in parallel — since the FDA has stated it won’t approve the NDA while Grace’s current contract manufacturer remains out of compliance, the second U.S.-based source isn’t just a hedge, it’s a live alternative path to approval. Whether investors view $2.10 a share as a fair price for that de-risking work is one question, but the strategy itself, funding a second manufacturing source rather than betting everything on one remediation effort, is a reasonable way to make sure this specific kind of stumble doesn’t happen twice.
